Tara Lin, MD, Oncology, Fairway, KS, The University of Kansas Hospital

TaraLLinMDMSCR

Oncology Fairway, KS

Hematologic Oncology

Associate Professor University of Kansas Cancer Center Kansas City, KS

Dr. Lin is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lin's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFELLOWSHIP
  • University of Maryland
    University of MarylandRESIDENCY
  • Virginia Commonwealth University School of Medicine
    Virginia Commonwealth University School of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • KS State Medical License
    KS State Medical License 2011 - 2021
  • LA State Medical License
    LA State Medical License 2008 - 2018
  • MD State Medical License
    MD State Medical License 2003 - 2008
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
    Tara L. Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
    Tara L. Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
    Tara L. Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Fate and Celyad’s CAR Therapies in Oncology Offer Potential to Amplify Efficacy with Multiple Doses
    Fate and Celyad’s CAR Therapies in Oncology Offer Potential to Amplify Efficacy with Multiple Doses
  • Group Traveling from Oregon Stops in KC on Bike Ride to Raise Money for Cancer Research
    Group Traveling from Oregon Stops in KC on Bike Ride to Raise Money for Cancer ResearchSeptember 17, 2018
  • Getting to the Root of the Problem by Targeting Cancer Stem Cells
    Getting to the Root of the Problem by Targeting Cancer Stem CellsMarch 01, 2017

Hospital Affiliations